Welcome to our dedicated page for Vallon Pharmaceuticals news (Ticker: VLON), a resource for investors and traders seeking the latest updates and insights on Vallon Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vallon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vallon Pharmaceuticals's position in the market.
Vallon Pharmaceuticals (NASDAQ: VLON) announced that CEO David Baker will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. This virtual event will feature a video webcast available on-demand starting January 10, 2022. Vallon focuses on developing innovative drugs for CNS disorders, with its lead product ADAIR targeting ADHD and narcolepsy.
Vallon Pharmaceuticals has announced the completion of patient enrollment in its pivotal SEAL study, evaluating ADAIR, an abuse-deterrent formulation of dextroamphetamine for ADHD treatment. With 53 out of 55 enrolled subjects successfully completing the study, Vallon anticipates reporting topline results in Q1 2022. If approved, ADAIR could potentially capture a share of the $9 billion U.S. ADHD market, targeting the growth segment of Adderall.
Vallon Pharmaceuticals (NASDAQ: VLON) reported its financial results for Q3 2021, with a net loss of $1.3 million and $9.1 million in cash reserves. The company is advancing its lead program, ADAIR, a novel abuse-deterrent formulation of dextroamphetamine, and expects to complete patient enrollment in its pivotal SEAL study by Q1 2022. Furthermore, Vallon initiated its second program, ADMIR, an abuse-deterrent formulation of methylphenidate, in partnership with Catalent. The company aims to address the $9 billion US ADHD market, showcasing significant development progress.
Vallon Pharmaceuticals (NASDAQ: VLON) is set to participate in a Virtual Investor Roundtable on November 18, 2021 at 3:00 PM ET. CEO David Baker and CMO Timothy Whitaker will lead the event alongside Stephen V. Faraone, Ph.D., an expert in ADHD. The event includes a presentation, a moderated discussion, and an interactive Q&A session, allowing attendees to submit questions live or beforehand. A live webcast will be available for those interested.
Vallon Pharmaceuticals (NASDAQ: VLON) will present at the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15, 2021, at 8:30 am ET. David Baker, President & CEO, will lead the presentation, which is part of Vallon's commitment to developing novel drugs aimed at preventing abuse in the treatment of CNS disorders. Following the presentation, management will participate in virtual one-on-one meetings with qualified investors. The event will be archived for 90 days on the company's website.
Vallon Pharmaceuticals (NASDAQ: VLON) announced significant progress in its drug development programs, ADAIR and ADMIR. The company is nearing completion of the SEAL study with approximately 75% of patient enrollment achieved, targeting Q1 2022 for completion and topline results. Additionally, the final formulation for ADMIR has been selected, with plans to file an IND for human trials. The company highlights a strong market need for abuse-deterrent ADHD medications, emphasizing its proprietary technology aimed at combating stimulant misuse.
Vallon Pharmaceuticals (NASDAQ: VLON) has announced the formation of its Scientific Advisory Board (SAB) to support its development of abuse-deterrent drug technology for CNS disorders. The initial appointments include leading experts in ADHD and stimulant abuse: Dr. Stephen V. Faraone, Dr. Jeffrey Newcorn, and Dr. Anthony Rostain. Vallon aims to leverage their expertise as it advances its lead candidates, ADAIR and ADMIR, designed to mitigate drug abuse potential.
Vallon Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel drugs for central nervous system disorders, announced that David Baker, President and CEO, will present at the Q3 Virtual Investor Summit on August 18, 2021, at 12:30 PM ET. The event will include a live video webcast of the presentation, accessible on the investor relations section of the Vallon website. Additionally, management will engage in virtual one-on-one meetings with qualified investors registered for the conference.
